[Interferon beta-1a (Avonex TM): clinical and MRI impacts]

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Relapsing-remitting multiple sclerosis (MS) is characterized by progressive neurological disability.
• Effective disease-modifying therapies are crucial for managing MS.
• Interferon beta-1a (Avonex) is an established treatment for MS.

Purpose of the Study:

• To evaluate the efficacy of interferon beta-1a (Avonex) in slowing neurological disability progression in relapsing-remitting MS.
• To assess the impact of Avonex on disability milestones and exacerbation frequency.
• To analyze the effect of Avonex on magnetic resonance imaging (MRI) lesion burden.

Main Methods:

• A phase III, double-blind, placebo-controlled, multicentric trial involving 301 patients with relapsing-remitting MS.
• Patients received weekly intramuscular injections of Avonex 6.0 MUI (30 micrograms) or placebo.
• Primary outcome: time to sustained physical disability progression (≥1.0 point on the Expanded Disability Status Scale - EDSS) at 6 months.

Main Results:

• Avonex significantly delayed time to sustained EDSS progression (p = 0.02).
• A 37% reduction in the risk of accumulating disability was observed over 104 weeks.
• Avonex treatment led to a 32% decrease in exacerbation frequency and reduced the number and volume of gadolinium-enhanced MRI lesions.

Conclusions:

• Interferon beta-1a (Avonex) is effective in slowing disability progression in relapsing-remitting MS.
• Avonex demonstrates significant clinical benefits, including reduced exacerbations and MRI lesion burden.
• The safety profile of Avonex was favorable, with no major adverse events reported.